Gemigliptin

Drug Profile

Gemigliptin

Alternative Names: Gemigliptin tartrate sesquihydrate; Gemiglo®; LC-150444; Zemiglo

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator LG Life Sciences
  • Developer LG Life Sciences; Sanofi
  • Class Antihyperglycaemics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Acute kidney injury

Most Recent Events

  • 10 Jul 2016 LG Life Sciences plans the phase III ZEUS II trial for Type-2 diabetes mellitus (Adjunctive treatment) in South Korea (PO) (NCT02831361)
  • 01 Apr 2016 Sanofi completes a phase-III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Russia (PO) (NCT02343926)
  • 01 Apr 2015 LG Life Sciences completes a phase III trial in Type II diabetes (adjunctive treatment) in USA (NCT01990469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top